Easterly Investment Partners LLC Boosts Holdings in Quanterix Co. (NASDAQ:QTRX)

Easterly Investment Partners LLC boosted its stake in Quanterix Co. (NASDAQ:QTRX) by 9.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 954,995 shares of the company’s stock after buying an additional 78,862 shares during the quarter. Easterly Investment Partners LLC’s holdings in Quanterix were worth $10,152,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of QTRX. KLP Kapitalforvaltning AS acquired a new position in shares of Quanterix in the 4th quarter valued at $66,000. Peapack Gladstone Financial Corp acquired a new position in Quanterix in the third quarter valued at $131,000. Levin Capital Strategies L.P. purchased a new stake in shares of Quanterix in the fourth quarter valued at about $159,000. Tallon Kerry Patrick acquired a new stake in shares of Quanterix during the fourth quarter worth about $169,000. Finally, Intech Investment Management LLC acquired a new position in Quanterix in the 3rd quarter valued at about $170,000. Institutional investors and hedge funds own 86.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have weighed in on QTRX. Canaccord Genuity Group decreased their price objective on Quanterix from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Scotiabank reissued an “outperform” rating on shares of Quanterix in a research note on Tuesday.

Quanterix Price Performance

Shares of NASDAQ:QTRX opened at $6.66 on Thursday. Quanterix Co. has a 12 month low of $6.30 and a 12 month high of $23.94. The firm has a market capitalization of $258.25 million, a price-to-earnings ratio of -6.28 and a beta of 1.33. The business’s 50 day simple moving average is $8.08 and its 200-day simple moving average is $10.72.

Quanterix (NASDAQ:QTRX) last posted its earnings results on Monday, March 17th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.03). The firm had revenue of $35.16 million during the quarter, compared to analyst estimates of $34.93 million. Quanterix had a negative net margin of 30.12% and a negative return on equity of 11.74%. On average, equities analysts anticipate that Quanterix Co. will post -0.98 earnings per share for the current year.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.